Streetbeat News

Stock Prices

TMBR

Timber Pharmaceuticals announced that its proposal to approve a merger agreement with Leo US and Leo Spiny Merger Sub was not approved by a majority of the outstanding shares entitled to vote, as per an SEC filing. A special meeting was held to vote on this matter.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 6:19 pm

NTES

NetEase's stock (NTES) is experiencing a rebound after the company reported its Q3 financial results. Benchmark, a financial firm, has increased its price target for NetEase from $130 to $140.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 6:12 pm

AGE

PFE

Serina Therapeutics Inc has licensed its POZ polymer technology to Pfizer Inc for research and development activities. Serina, which is set to merge with AgeX Therapeutics Inc in an all-stock transaction, will continue under the Serina name post-merger. AgeX Therapeutics' stock (AGE) is trading lower on heavy volume, with shares down 28.3% at $0.42.

Portfolio Pulse from Vandana Singh

November 17, 2023 | 6:10 pm

AYRWF

CBSTF

GTBIF

TSNDF

VRNOF

U.S. cannabis operators reported varied Q3 results, with Green Thumb Industries (GTBIF) and Verano Holdings (VRNOF) showing strong performances, while The Cannabist Company (CBSTF) and Ayr Wellness (AYRWF) lagged. Green Thumb's revenue growth and stock buyback program, Verano's cost efficiency and revised cash flow guidance, and TerrAscend's (TSNDF) revenue growth and debt reduction were highlights. The disparities among companies underscore the importance of operational efficiency for long-term success.

Portfolio Pulse from Alexander Teicher

November 17, 2023 | 6:07 pm

WSM

RBC Capital analyst Steven Shemesh has maintained an Outperform rating on Williams-Sonoma (NYSE:WSM) and increased the price target from $150 to $165.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 6:04 pm

BEAM

Beam Therapeutics' stock is trading higher, potentially in response to news that CRISPR, a company in the same sector, received regulatory authorization for the first CRISPR/Cas9 gene-edited therapy.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 6:02 pm

NICE

RBC Capital analyst Rishi Jaluria has reiterated an Outperform rating on NICE Ltd. (NASDAQ:NICE) and maintained a price target of $238.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 6:01 pm

PCG

PG&E (NYSE:PCG) has received 8 analyst ratings in the last quarter with an average price target of $17.88, slightly above its current price of $17.85. The ratings include 3 bullish, 2 somewhat bullish, and 3 indifferent, with no bearish ratings. The current average price target represents a 0.67% decrease from the previous target of $18.00. Analysts rate stocks to provide investment guidance, but their advice may be subject to error.

Portfolio Pulse from Benzinga Insights

November 17, 2023 | 6:00 pm

LEN

SNPS

On CNBC's Halftime Report, the final trades segment featured recommendations for Lennar Corporation and Synopsys, Inc. The commentators provided their insights on these stocks, suggesting them as potential investment opportunities.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 6:00 pm

DRTS

Alpha Tau Medical (NASDAQ:DRTS) has received 4 analyst ratings in the last quarter, with an average 12-month price target of $12.25, a high of $23.00, and a low of $8.00. The current average price target represents a 2.08% increase from the previous target of $12.00. The ratings consist of 2 bullish and 2 somewhat bullish, with no indifferent, somewhat bearish, or bearish ratings.

Portfolio Pulse from Benzinga Insights

November 17, 2023 | 6:00 pm